Our research focuses on using UK Biobank data, specifically genomics, proteomics, and imaging datasets, to explore associations between these biological features and cardiometabolic outcomes, such as heart disease, diabetes, and obesity. By integrating genetic variants, protein expression profiles, and advanced imaging data (e.g., the MRI scans), we aim to identify biomarkers and causal pathways underlying cardiometabolic diseases. This comprehensive approach leverages high-dimensional data to understand how genetic and protein interactions influence disease progression and outcomes. The genomics data will help us pinpoint genetic predispositions, while proteomics will offer insights into circulating proteins that impact metabolic functions. Imaging data will enable detailed phenotyping of organs and tissues, revealing structural and functional abnormalities linked to cardiometabolic risk. Ultimately, this research seeks to uncover novel targets for therapeutic interventions and enhance precision medicine approaches in cardiometabolic health, contributing to improved prediction, prevention, and management of these widespread conditions.
